(Q34127433)

31 July 2017

1 reference

title

Amprenavir: a review of its clinical potential in patients with HIV infection (English)

1 reference

31 July 2017

S Noble

1

1 reference

31 July 2017

K L Goa

series ordinal

2

1 reference

31 July 2017

1 December 2000

1 reference

31 July 2017

1 reference

31 July 2017

60

1 reference

31 July 2017

6

1 reference

31 July 2017

1383-1410

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200060060-00012

31 July 2017

0 references

cites work

The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).

1 reference

12 December 2020

Antiretroviral drug guidelines for the treatment of HIV infection: should protease inhibitors always be included in the initial regimen or not?

1 reference

12 December 2020

Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men.

1 reference

12 December 2020

Analysis of HIV-1 clinical trials: statistical magic? The AVANTI Steering Committee

1 reference

12 December 2020

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

12 December 2020

HIV protease inhibitors stimulate hepatic triglyceride synthesis.

1 reference

12 December 2020

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection

1 reference

12 December 2020

Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy

1 reference

12 December 2020

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies

1 reference

12 December 2020

Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease

1 reference

12 December 2020

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

1 reference

12 December 2020

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

1 reference

12 December 2020

Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers

1 reference

12 December 2020

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity

1 reference

12 December 2020

Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome

1 reference

12 December 2020

The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors

1 reference

12 December 2020

Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

1 reference

12 December 2020

Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function

1 reference

12 December 2020

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

1 reference

12 December 2020

Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir

1 reference

12 December 2020

Protease inhibitors for the treatment of human immunodeficiency virus infection

1 reference

12 December 2020

"Buffalo hump" in men with HIV-1 infection.

1 reference

12 December 2020

In vitro selection and characterization of VX-478 resistant HIV-1 variants.

1 reference

12 December 2020

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

12 December 2020

HIV-protease inhibitors

1 reference

12 December 2020

Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro

1 reference

12 December 2020

Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.

1 reference

12 December 2020

HIV protease inhibitors block adipogenesis and increase lipolysis in vitro

1 reference

12 December 2020

Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.

1 reference

12 December 2020

Lipodystrophy in patients naive to HIV protease inhibitors

1 reference

12 December 2020

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

12 December 2020

In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors

1 reference

12 December 2020

A risk-benefit assessment of HIV protease inhibitors

1 reference

12 December 2020

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

1 reference

12 December 2020

Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.

1 reference

12 December 2020

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

1 reference

12 December 2020

In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease

1 reference

12 December 2020

Dietary fat alters HIV protease inhibitor-induced metabolic changes in mice

1 reference

12 December 2020

10.2165/00003495-200060060-00012

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1045752907

0 references

Fatcat ID

release_khydoxejwvh6jbq7endrxnalhe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/khydoxejwvh6jbq7endrxnalhe

24 November 2022

mapped directly with Wikidata item

1 reference